88692164 - NOVOCOL PHARMA

Information

• Trademark
• 88692164

• Source

• Serial Number

  88692164

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 10 - Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth
  • 35 - Advertising
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 45 - Legal services

• Filing Date

  November 14, 2019
  5 years ago

• Transaction Date

  October 17, 2024
  a month ago

• Status Date

  April 16, 2024
  7 months ago

• Published for Opposition Date

  February 20, 2024
  9 months ago

• Location Date

  April 16, 2024
  7 months ago

• Status Code

  688

• Current Location

  INTENT TO USE SECTION

  Employee Name

  ALLEN, BIANCA

• Attorney Docket Number

  015343.00366

  Attorney Name

  Jason J. Mazur

  Law Office Assigned Location Code

  N50

• Owners

  • Septodont Holding SAS

Case File Statements

• GS0401: (Based on 44(e)) Contract manufacturing of clinical batches of pharmaceuticals; (Based on Intent to Use) consulting services relating to pharmaceutical manufacturing and batch biological treatment batches; none of the foregoing for the treatment of cancer or oncological diseases and disorders
• DM0000: The mark consists of a design element in the top-left corner of overlapping arced lines with the bottom line in red and the top line in blue, with the word "NOVOCOL" in blue lower-case design and underneath to the right the word "PHARMA" in smaller red lower-case design.
• GS0051: (Based on 44(e)) Pharmaceutical products, namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations for treatment of dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders
• CC0000: The color(s) blue and red is/are claimed as a feature of the mark.
• GS0351: (Based on 44(e)) Business consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies, method development, formal stability, registration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders
• GS0451: (Based on 44(e)) Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; (Based on Intent to Use) consulting services relating to pharmaceuticals in the field of regulatory compliance, namely, regulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders
• DS0000: "PHARMA"
• GS0101: (Based on 44(e)) Drug delivery systems, consisting of needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders
• GS0421: (Based on 44(e)) Pharmaceutical drug development services, namely, the formulation of new dosage forms and the reformulation of existing drug products; (Based on Intent to Use) consulting services relating to clinical testing, inspection, or research of pharmaceuticals; consulting services relating to conducting pharmaceutical stability studies and formal stability studies; consulting services relating to the development of chemical production methods; consulting services relating to registration batch research and commercial pharmaceutical products development; none of the foregoing for the treatment of cancer or oncological diseases and disorders

Case File Event Statements

• 11/18/2019 - 5 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 11/20/2019 - 5 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 11/21/2019 - 5 years ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 2/19/2020 - 4 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 2/20/2020 - 4 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/20/2020 - 4 years ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/20/2020 - 4 years ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 3/13/2020 - 4 years ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/13/2020 - 4 years ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 3/13/2020 - 4 years ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 3/18/2020 - 4 years ago

  11 - SUSPENSION LETTER WRITTEN Type: CNSL

• 3/18/2020 - 4 years ago

  12 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 3/18/2020 - 4 years ago

  13 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 9/18/2020 - 4 years ago

  14 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 9/18/2020 - 4 years ago

  15 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 9/18/2020 - 4 years ago

  16 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 9/21/2020 - 4 years ago

  17 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 12/16/2020 - 3 years ago

  18 - ASSIGNED TO LIE Type: ALIE

• 12/28/2020 - 3 years ago

  19 - ASSIGNED TO LIE Type: ALIE

• 12/29/2020 - 3 years ago

  20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/29/2020 - 3 years ago

  21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 12/30/2020 - 3 years ago

  22 - SUSPENSION LETTER WRITTEN Type: CNSL

• 12/30/2020 - 3 years ago

  23 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 12/30/2020 - 3 years ago

  24 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 7/1/2021 - 3 years ago

  25 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 1/3/2022 - 2 years ago

  29 - ASSIGNED TO LIE Type: ALIE

• 7/1/2021 - 3 years ago

  26 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 7/1/2021 - 3 years ago

  27 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 12/28/2021 - 2 years ago

  28 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 1/10/2022 - 2 years ago

  30 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 1/10/2022 - 2 years ago

  31 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/10/2022 - 2 years ago

  32 - SUSPENSION LETTER WRITTEN Type: CNSL

• 1/10/2022 - 2 years ago

  33 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 1/10/2022 - 2 years ago

  34 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 3/1/2022 - 2 years ago

  35 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 3/1/2022 - 2 years ago

  36 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 3/1/2022 - 2 years ago

  37 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 3/1/2022 - 2 years ago

  38 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 3/9/2022 - 2 years ago

  39 - ASSIGNED TO EXAMINER Type: DOCK

• 7/18/2022 - 2 years ago

  40 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK

• 8/8/2022 - 2 years ago

  41 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 8/8/2022 - 2 years ago

  42 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 8/8/2022 - 2 years ago

  43 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 2/1/2023 - a year ago

  44 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 2/8/2023 - a year ago

  45 - ASSIGNED TO LIE Type: ALIE

• 2/8/2023 - a year ago

  46 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 2/8/2023 - a year ago

  47 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 2/8/2023 - a year ago

  48 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 2/8/2023 - a year ago

  49 - SUSPENSION LETTER WRITTEN Type: CNSL

• 2/8/2023 - a year ago

  50 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 2/8/2023 - a year ago

  51 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 9/2/2023 - a year ago

  52 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK

• 9/18/2023 - a year ago

  53 - ASSIGNED TO EXAMINER Type: DOCK

• 9/27/2023 - a year ago

  54 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK

• 10/2/2023 - a year ago

  55 - SUSPENSION INQUIRY WRITTEN Type: CNSI

• 10/2/2023 - a year ago

  56 - INQUIRY TO SUSPENSION E-MAILED Type: GNSI

• 10/2/2023 - a year ago

  57 - NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Type: GNS2

• 12/21/2023 - 11 months ago

  58 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI

• 12/23/2023 - 11 months ago

  59 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/23/2023 - 11 months ago

  60 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 1/16/2024 - 10 months ago

  61 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 1/16/2024 - 10 months ago

  62 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 1/16/2024 - 10 months ago

  63 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 1/16/2024 - 10 months ago

  64 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 1/17/2024 - 10 months ago

  65 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 2/1/2024 - 9 months ago

  67 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 1/31/2024 - 10 months ago

  66 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 2/1/2024 - 9 months ago

  68 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 2/8/2024 - 9 months ago

  69 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA

• 2/20/2024 - 9 months ago

  70 - PUBLISHED FOR OPPOSITION Type: PUBO

• 3/4/2024 - 8 months ago

  71 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 3/11/2024 - 8 months ago

  72 - ASSIGNED TO PETITION STAFF Type: APET

• 3/12/2024 - 8 months ago

  73 - CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED Type: CHPB

• 10/16/2024 - a month ago

  76 - TEAS STATEMENT OF USE RECEIVED Type: EISU

• 10/16/2024 - a month ago

  75 - SOU TEAS EXTENSION RECEIVED Type: EEXT

• 4/16/2024 - 7 months ago

  74 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM